Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells

Breast Cancer Research

Volumn 8, Issue 6, 2006, Pages

  Saito, Hiroaki ^a   Dubsky, Peter ^a   Dantin, Carole ^a   Finn, Olivera J ^b   Banchereau, Jacques ^a   Palucka, A Karolina ^a  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; CYTOKINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; HLA A ANTIGEN; MUCIN 1; SURVIVIN; BIRC5 PROTEIN, HUMAN; CCNB1 PROTEIN, HUMAN; CYCLIN B; INHIBITOR OF APOPTOSIS PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; MUC1 PROTEIN, HUMAN; MUCIN; TUMOR ANTIGEN; TUMOR PROTEIN;

ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CD8+ T LYMPHOCYTE; CELL KILLING; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; TUMOR IMMUNITY; BREAST TUMOR; DENDRITIC CELL; FEMALE; IMMUNOLOGY;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; CYCLIN B; CYCLIN B1; DENDRITIC CELLS; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON-GAMMA; MICROTUBULE-ASSOCIATED PROTEINS; MUCIN-1; MUCINS; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 35348863525     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1621     Document Type: Article

References (32)

1. Ries L Eisner M Kosary C SEER Cancer Statistics Review, 1975-2000 Bethesda, MD: National Cancer Institute 2003.
2. Disis ML Bernhard H Gralow JR Hand SL Emery SR Calenoff E Cheever MA Immunity to the HER-2/neu oncogenic protein Ciba Found Symp 1994, 187:198-207 7540970
3. Disis ML Cheever MA HER-2/neu protein: A target for antigen-specific immunotherapy of human cancer Adv Cancer Res 1997, 71:343-371 9111870
4. Albert ML Darnell JC Bender A Francisco LM Bhardwaj N Darnell RB Tumor-specific killer cells in paraneoplastic cerebellar degeneration Nat Med 1998, 4:1321-1324 10.1038/3315 9809559
5. Nagorsen D Scheibenbogen C Schaller G Leigh B Schmittel A Letsch A Thiel E Keilholz U Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients Int J Cancer 2003, 105:221-225 10.1002/ijc.11052 12673683
6. Feuerer M Beckhove P Bai L Solomayer EF Bastert G Diel IJ Pedain C Oberniedermayr M Schirrmacher V Umansky V Therapy of human tumors in NOD/ SCID mice with patient-derived reactivated memory T cells from bone marrow Nat Med 2001, 7:452-458 10.1038/86523 11283672
7. Kao H Marto JA Hoffmann TK Shabanowitz J Finkelstein SD Whiteside TL Hunt DF Finn OJ Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells J Exp Med 2001, 194:1313-1323 10.1084/jem.194.9.1313 11696596
8. Andersen MH Pedersen LO Capeller B Brocker EB Becker JC thor Straten P Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients Cancer Res 2001, 61:5964-5968 11507035
9. Hsu FJ Benike C Fagnoni F Liles TM Czerwinski D Taidi B Engleman EG Levy R Vaccination of patients with B-cell lymphoma using autologous antigen- pulsed dendritic cells Nat Med 1996, 2:52-58 10.1038/nm0196-52 8564842
10. Nestle FO Alijagic S Gilliet M Sun Y Grabbe S Dummer R Burg G Schadendorf D Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nat Med 1998, 4:328-332 10.1038/nm0398-328 9500607
11. Thurner B Haendle I Roder C Dieckmann D Keikavoussi P Jonuleit H Bender A Maczek C Schreiner D von den Driesch P Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma J Exp Med 1999, 190:1669-1678 10.1084/jem.190.11.1669 10587357
12. Timmerman JM Czerwinski DK Davis TA Hsu FJ Benike C Hao ZM Taidi B Rajapaksa R Caspar CB Okada CY Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients Blood 2002, 99:1517-1526 10.1182/blood.V99.5.1517 11861263
13. Banchereau J Palucka AK Dhodapkar M Burkeholder S Taquet N Rolland A Taquet S Coquery S Wittkowski KM Bhardwaj N Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine Cancer Res 2001, 61:6451-6458 11522640
14. Brossart P Wirths S Stuhler G Reichardt VL Kanz L Brugger W Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells Blood 2000, 96:3102-3108 11049990
15. Banchereau J Palucka AK Dendritic cells as therapeutic vaccines against cancer Nat Rev Immunol 2005, 5:296-306 10.1038/nri1592 15803149
16. Albert ML Sauter B Bhardwaj N Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs Nature 1998, 392:86-89 10.1038/32183 9510252
17. Nouri-Shirazi M Banchereau J Bell D Burkeholder S Kraus ET Davoust J Palucka KA Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses J Immunol 2000, 165:3797-3803 11034385
18. Berard F Blanco P Davoust J Neidhart-Berard EM Nouri-Shirazi M Taquet N Rimoldi D Cerottini JC Banchereau J Palucka AK Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells J Exp Med 2000, 192:1535-1544 10.1084/ jem.192.11.1535 11104796
19. Boczkowski D Nair SK Snyder D Gilboa E Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo J Exp Med 1996, 184:465-472 10.1084/jem.184.2.465 8760800
20. Ashley DM Faiola B Nair S Hale LP Bigner DD Gilboa E Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors J Exp Med 1997, 186:1177-1182 10.1084/jem.186.7.1177 9314567
21. Ribas A Butterfield LH Glaspy JA Economou JS Cancer immunotherapy using gene-modified dendritic cells Curr Gene Ther 2002, 2:57-78 10.2174/ 1566523023348129 12108974
22. Phan V Errington F Cheong SC Kottke T Gough M Altmann S Brandenburger A Emery S Strome S Bateman A A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines Nat Med 2003, 9:1215-1219 10.1038/nm923 12925849
23. Neidhardt-Berard EM Berard F Banchereau J Palucka AK Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes Breast Cancer Res 2004, 6:R322-R328 468631 15217499 10.1186/bcr794
24. Paczesny S Shi H Saito H Mannoni P Fay J Banchereau J Palucka AK Measuring melanoma-specific cytotoxic T lymphocytes elicited by dendritic cell vaccines with a tumor inhibition assay in vitro J Immunother 2005, 28:148-157 10.1097/01.cji.0000154247.97254.ef 15725959
25. Finn OJ Jerome KR Henderson RA Pecher G Domenech N Magarian-Blander J Barratt-Boyes SM MUC-1 epithelial tumor mucin-based immunity and cancer vaccines Immunol Rev 1995, 145:61-89 10.1111/j.1600-065X.1995.tb00077.x 7590831
26. Hiltbold EM Vlad AM Ciborowski P Watkins SC Finn OJ The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells J Immunol 2000, 165:3730-3741 11034378
27. Vlad AM Kettel JC Alajez NM Carlos CA Finn OJ MUC1 immunobiology: From discovery to clinical applications Adv Immunol 2004, 82:249-293 14975259
28. Tamm I Wang Y Sausville E Scudiero DA Vigna N Oltersdorf T Reed JC IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs Cancer Res 1998, 58:5315-5320 9850056
29. Schmitz M Diestelkoetter P Weigle B Schmachtenberg F Stevanovic S Ockert D Rammensee HG Rieber EP Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides Cancer Res 2000, 60:4845-4849 10987296
30. Idenoue S Hirohashi Y Torigoe T Sato Y Tamura Y Hariu H Yamamoto M Kurotaki T Tsuruma T Asanuma H A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins Clin Cancer Res 2005, 11:1474-1482 10.1158/1078-0432.CCR-03-0817 15746049
31. Bohnenkamp HR Coleman J Burchell JM Taylor-Papadimitriou J Noll T Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I-tetramers Cell Immunol 2005, 231:112-125 10.1016/j.cellimm.2004.12.007
32. Palucka AK Ueno H Connolly J Kerneis-Norvell F Blanck JP Johnston DA Fay J Banchereau J Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity J Immunother 2006, 29:545-557 10.1097/ 01.cji.0000211309.90621.8b 16971810